TITLE

Circulating Serologic and Molecular Biomarkers in Malignant Melanoma

AUTHOR(S)
PALMER, SHANIQUE R.; ERICKSON, LOIU A.; ICHETOYKIN, ILIA; KNAUER, DANIEL J.; MARKOVIC, SVETOMIR N.
PUB. DATE
October 2011
SOURCE
Mayo Clinic Proceedings;Oct2011, Vol. 86 Issue 10, p981
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90% of deaths from cutaneous malignancies. it remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphoiogic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.
ACCESSION #
66616746

 

Related Articles

  • Identification of Biomarkers in an Oral Malignant Melanoma Case with Potential for Therapeutic Intervention#. Pai, Rekha B.; Pai, S. Balakrishna; Lalitha, R. M.; Kumaraswamy, S. V.; Lalitha, N.; Johnston, Randal N.; Bhargava, M. Krishna // Internet Journal of Oncology;2010, Vol. 7 Issue 1, p3 

    A 32-year old female patient presented with the tumor of the oral cavity at the Kidwai Memorial Institute of Oncology, Bangalore, India. Clinical examination and histopathological analyses confirmed the neoplasm as malignant melanoma. This rare melanoma of the buccal mucosa expressed...

  • Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma. ARMAND-LABIT, Virginie; MEYER, Nicolas; CASANOVA, Anne; BONNABAU, Henri; PLATZER, Valérie; TOURNIER, Emilie; SANSAS, Benoît; VERDUN, Stéphane; THOUVENOT, Benoit; HILSELBERGER, Benoit; DONCESCU, Andrei; LAMANT, Laurence; LACROIX-TRIKI, Magali; FAVRE, Gilles; PRADINES, Anne // Acta Dermato-Venereologica;Jan2016, Vol. 96 Issue 1, p29 

    No specific biomarkers for prognostication or evaluation of tumour load in melanoma have been reported to our knowledge. MicroRNAs (miRNAs) are strongly implicated in oncogenesis and tumour progression, and their circulating forms have been studied as potential biomarkers in oncology. The aim of...

  • HISTOPATHOLOGICAL MARKERS PROFILE OF LENTIGO MALIGNA/LENTIGO MALIGNA MELANOMA IN A CENTRE IN BUCHAREST - ROMANIA FROM 2003 TO 2013. HIGHLIGHTING THE HISTOPATHOLOGICAL PROGNOSTIC MARKERS. BRÎNZEA, ALICE; NEDELCU, ROXANA IOANA; MINCĂ, DANA GALIETA // Acta Medica Transilvanica;sep2014, Vol. 19 Issue 3, p187 

    Lentigo maligna is the melanoma “in situ”. When invades the dermis, it becomes lentigo maligna melanoma and the prognostic features are identical to all other melanomas according to size and level of invasion. The rate of progression of LM to LMM is 5-50%. LMM represents 4-15% of all...

  • DC-HIL+ CD14+ HLA-DRno/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma. Turrentine, Jake; Chung, Jin-Sung; Nezafati, Kaveh; Tamura, Kyoichi; Harker-Murray, Amy; Huth, James; Sharma, Rohit R; Harker, David B; Ariizumi, Kiyoshi; Cruz, Ponciano D // Journal of Investigative Dermatology;Nov2014, Vol. 134 Issue 11, p2839 

    The article discusses the study that determines the potential of DC-HIL receptor in inhibiting T-cell function. It describes the method of the study that observes how melanoma-bearing mice harbors an expanded population of DC-HIL receptor. It outlines the findings of the study which indicates...

  • Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Straume, O.; Akslen, L. A. // British Journal of Cancer;10/17/2005, Vol. 93 Issue 8, p933 

    The ID1 protein, an inhibitor of basic helix-loop-helix transcription factors, has been involved in multiple cellular processes including cell cycle regulation, apoptosis, and angiogenesis. To evaluate the importance of ID1 in malignant melanoma, tumour cell expression was examined by...

  • Melanin Pigments and Melanosomal Proteins as Differentiation Markers Unique to Normal and Neoplastic Melanocytes. Jimbow, Kowichi; Lee, Simon K.; King, Michael G.; Hara, Hiroyuki; Hua Chen; Dakour, Jamal; Marusyk, Halyna // Journal of Investigative Dermatology;Mar1993, Vol. 100 Issue 3, p259S 

    This report introduces some aspects of our current basic research focus on the unique metabolic pathways within the melanocyte. Using this approach, we hope to gain a better understanding of the pathophysiology of malignant melanoma and develop early laboratory diagnostic tests for this disease....

  • Melanoma Biomarkers Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy. Haass, Nikolas K.; Smalley, Keiran S. M. // Molecular Diagnosis & Therapy;Oct2009, Vol. 13 Issue 5, p283 

    Melanoma is the most devastating form of skin cancer and represents a leading cause of cancer death, particularly in young adults. As even relatively small melanomas can readily metastasize, accurate staging of progression is critical. Diagnosis is typically made on the basis of histopathologic...

  • Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Khoja, Leila; Lorigan, Paul; Zhou, Cong; Lancashire, Matthew; Booth, Jessica; Cummings, Jeff; Califano, Raffaele; Clack, Glen; Hughes, Andrew; Dive, Caroline // Journal of Investigative Dermatology;Jun2013, Vol. 133 Issue 6, p1582 

    The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as...

  • Melanoma: A more accurate diagnosis. Swami, Meera // Nature Reviews Cancer;Jun2009, Vol. 9 Issue 6, p385 

    The article presents research highlights from the field of melanoma research based on the original research paper "A multi-marker assay to distinguish malignant melanomas from benign nevi," by M. Kashani-Sabet et al. that appeared in the March 30, 2009 issue of "Proceedings of the National...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics